


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (original) A compound of the formula:



wherein A, B and D are independently chosen from either N or C, with the provision that at least one of A, B or D is N;

E is C or N;

R is H or C₁₋₄alkyl;

R² and R³ are independently H, C₁₋₃ alkyl, C₂₋₃ alkenyl, or R² and R³ taken together can form a 5 or 6 member ring;


X is hydrogen, halogen, C₁₋₄alkyl, or CF₃; and

the dashed bond may be a single bond or a double bond;

and pharmaceutically acceptable salts and solvates.

2. (original) The compound of claim 1, wherein the compound is 2-(8-bromo-benzo-[1,2-b;4,5-b']difuran-4-yl) imidazoline hydrochloride.

3. (currently amended) A method for lowering ~~intraocular~~ intraocular pressure and providing neuroprotection comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a compound of the formula:



wherein A, B and D are independently chosen from either N or C, with the provision that at least one of A, B or D is N;

E is C or N;

R is H or C₁₋₄alkyl;

R² and R³ are independently H, C₁₋₃ alkyl, C₂₋₃ alkenyl, or R² and R³ taken together can form a 5 or 6 member ring;


X is hydrogen, halogen, C₁₋₄alkyl, or CF₃; and

the dashed bond may be a single bond or a double bond;

and pharmaceutically acceptable salts and solvates.

4. (original) The method of claim 3, wherein the compound is 2-(8-bromo-benzo-[1,2-b;4,5-b"]difuran-4-yl) imidazoline hydrochloride.

5. (original) A composition for lowering and controlling normal or elevated intraocular pressure and providing ocular neuroprotection, comprising a compound of the formula:



wherein A, B and D are independently chosen from either N or C, with the provision that at least one of A, B or D is N;

E is C or N;

R is H or C₁₋₄alkyl;

R^2 and R^3 are independently H, C_{1-3} alkyl, C_{2-3} alkenyl, or R^2 and R^3 taken together can form a 5 or 6 member ring;

X is hydrogen, halogen, C_{1-4} alkyl, or CF_3 ; and

the dashed bond may be a single bond or a double bond;

and pharmaceutically acceptable salts and solvates.

6. (original) The composition of claim 5, wherein the compound is 2-(8-bromo-benzo-[1,2-b;4,5-b"]difuran-4-yl) imidazoline hydrochloride.

7. (original) The composition of claim 6, further comprising ophthalmologically acceptable preservatives.

8. (original) The composition of claim 6, further comprising ophthalmologically acceptable surfactants.

9. (original) The composition of claim 6, further comprising an agent to increase viscosity.

10. (original) The composition of claim 9, wherein the agent is selected from the group consisting of hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, and polyvinylpyrrolidone.

11. (original) The composition of claim 6, further comprising ophthalmologically acceptable preservatives, ophthalmologically acceptable surfactants and at least one agent to increase viscosity.

12. (original) The composition of claim 6, further defined as a topical ophthalmic suspension or solution having a pH of about 5 to about 8.

13. (original) The composition of claim 12, wherein the concentration of the compound is from .01% to 5% by weight.

14. (original) The composition of claim 13, wherein the composition of the compound is from .25% to 2% by weight.

15. (original) The composition of claim 6, further comprising at least one agent selected from the group consisting of β -blockers, prostaglandins, carbonic anhydrase inhibitors, and miotics.

16. (original) The composition of claim 6, further comprising at least one agent selected from the group consisting of calcium channel blockers and NMDA antagonists.